BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

29 related articles for article (PubMed ID: 38602773)

  • 1. A case of intracranial hemorrhage caused by combined dabrafenib and trametinib therapy for metastatic melanoma.
    Lee le M; Feun L; Tan Y
    Am J Case Rep; 2014 Oct; 15():441-3. PubMed ID: 25305754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
    Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
    N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
    Dummer R; Hauschild A; Santinami M; Atkinson V; Mandalà M; Kirkwood JM; Chiarion Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Lesimple T; Plummer R; Dasgupta K; Gasal E; Tan M; Long GV; Schadendorf D
    N Engl J Med; 2020 Sep; 383(12):1139-1148. PubMed ID: 32877599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma.
    Hennemann A; Puzenat E; Decreuse M; Vuillier F; Nardin C; Aubin F
    Melanoma Res; 2024 Jun; 34(3):280-282. PubMed ID: 38602773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trametinib (MEKINIST°) Metastatic or inoperable BRAF V600-positive melanoma: a few extra months of life.
    Prescrire Int; 2016 Dec; 25(177):285-288. PubMed ID: 30758923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
    Dhillon S
    Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of melanocytic nevi under vemurafenib, followed by combination therapy with dabrafenib and trametinib for metastatic melanoma.
    Giurcaneanu C; Nitipir C; Popa LG; Forsea AM; Popescu I; Bumbacea RS
    Acta Dermatovenerol Croat; 2015; 23(2):114-21. PubMed ID: 26228819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.
    Khunger A; Khunger M; Velcheti V
    Ther Adv Respir Dis; 2018; 12():1753466618767611. PubMed ID: 29595366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
    Jarkowski A; Norris L; Trinh VA
    Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature.
    Arıkan R; Telli TA; Demircan NC; Başoğlu T; Ercelep Ö; Atasoy BM; Özgüven S; Dane F; Yumuk PF
    Curr Probl Cancer; 2021 Apr; 45(2):100668. PubMed ID: 33127167
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.